Skip to content
PubMed This is a summary of 6 peer-reviewed journal articles Updated
Clinical Immunology · Immunodeficiency 107

Testing for the Hidden Defect: Diagnosis and Interpretation

At a Glance

Immunodeficiency 107 is usually diagnosed by matching severe or invasive Staphylococcus aureus infections with a pathogenic or likely pathogenic loss-of-function variant in one copy of OTULIN. Routine blood tests may be normal, and a VUS does not confirm the condition.

Diagnosing Immunodeficiency 107 (IMD107) can be a confusing journey because it does not show up on the standard tests doctors use to check the immune system. Finding out that your standard blood tests are normal, despite experiencing severe infections, is a common and validating step in this process. While most immune disorders involve low white blood cell counts or missing antibodies, IMD107 involves a vulnerability within the structure of your skin and lung cells [1][2].

The Genetic Investigation

Because blood work is typically unremarkable, a central way to diagnose IMD107 is through genetic testing correlated carefully with your clinical symptoms. A molecular diagnosis requires finding a specific type of change in the OTULIN gene [2].

The hallmark of IMD107 is a monoallelic loss-of-function variant. This means:

  • Monoallelic (Heterozygous): You have one working copy and one altered copy of the gene [3].
  • Loss-of-Function: The altered copy provides no useful instructions, leaving you with a reduced amount of OTULIN protein (this state is called haploinsufficiency) [2][3].

Common types of variants that cause this include nonsense mutations, frameshift mutations, or splice-site variants [2][4].

When Genetics Aren’t Enough: VUS and Functional Testing

Sometimes, a genetic test finds a change in the OTULIN gene, but the lab isn’t sure if it actually causes the disease. This is called a Variant of Unknown Significance (VUS) [2]. A VUS does not establish disease and should not drive predictive testing for family members or treatment decisions.

In specialized research settings, functional testing on a skin biopsy has been used to study variants by looking for markers like linear ubiquitin build-up, Caveolin-1 accumulation, and alpha-toxin sensitivity in dermal fibroblasts [1]. However, these are research-level, non-routine tests with uncertain clinical validation. A skin biopsy is an invasive procedure and should not be pursued casually to investigate wound healing; it may only be considered through an expert laboratory after genetics consultation [1][5].

A Discussion Checklist for Your Reports

When you review your genetic report with a specialist, ask whether the laboratory evaluated the following details:

  • Gene Name: OTULIN.
  • Zygosity: Heterozygous (only one copy affected).
  • Variant Nomenclature: Includes DNA (c.) and protein (p.) notations.
  • Classification: Is it definitively classified as Pathogenic or Likely Pathogenic, rather than a VUS?
  • Mechanism: Is it understood to be a “loss-of-function” or “haploinsufficiency” mutation? [6].
  • Methodology: Did the test include sequencing as well as deletion/duplication analysis (copy-number analysis)? [4].

The Importance of Family Testing

Because IMD107 is an autosomal dominant condition, each child of a person who is heterozygous for a confirmed pathogenic variant has a 50% chance of carrying the variant [2]. A sibling’s risk is only 50% if one of the parents carries the variant; if the mutation arose de novo (new in you), the sibling risk is usually much lower.

Because the condition is incompletely penetrant, a family member could have the same genetic variant but have no history of severe infections [1][3]. Meeting with a genetic counselor is essential. They can help explain parental testing, clarify transmission risks, and explicitly guide family members on the implications of cascade testing [3][6].

Common questions in this guide

What genetic result supports a diagnosis of IMD107?
A diagnosis is supported by a pathogenic or likely pathogenic loss-of-function change in one copy of OTULIN, interpreted alongside the person’s infection history and other clinical findings. Nonsense, frameshift, and splice-site changes are examples of variants that may cause this pattern.
Can routine immune blood tests be normal with IMD107?
Yes. Blood counts and antibody testing may be unrevealing because IMD107 involves a problem in tissue-cell structure and function rather than the low blood counts or missing antibodies seen in some immune disorders. Severe infections despite normal results warrant specialist evaluation.
What does a VUS in the OTULIN gene mean?
A variant of uncertain significance, or VUS, is a genetic change whose connection to disease is not known. A VUS does not confirm IMD107 and should not be used alone to predict the condition in relatives or make treatment decisions.
What should I look for in my OTULIN genetic report?
Look for the OTULIN gene, a heterozygous result, DNA and protein notation, and a pathogenic or likely pathogenic classification rather than a VUS. Ask whether the laboratory included sequencing plus deletion/duplication, or copy-number, analysis and whether the change is expected to cause loss of function or reduced gene dosage.
How is IMD107 inherited, and could a carrier have no symptoms?
IMD107 is autosomal dominant. Each child of a person with a confirmed pathogenic variant in one copy of OTULIN has a 50% chance of inheriting it, but not every carrier develops severe infections because the condition is incompletely penetrant. A new, or de novo, variant can make the risk to siblings much lower.
Is a skin biopsy routinely used to diagnose IMD107?
Functional testing of skin cells has been used in research to study markers such as linear ubiquitin build-up, Caveolin-1 accumulation, and alpha-toxin sensitivity. It is not a routine, clinically validated test and should only be considered through an expert laboratory after genetics consultation.

Get notified when new evidence is published on immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (6)
  1. 1

    Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin.

    Spaan AN, Neehus AL, Laplantine E, et al.

    Science (New York, N.Y.) 2022; (376(6599)):eabm6380 doi:10.1126/science.abm6380.

    PMID: 35587511
  2. 2

    Novel genotypes, phenotypes, and triggers in humans with OTULIN haploinsufficiency.

    van der Linden TJ, Arts RJW, Biggs CM, et al.

    Journal of human immunity 2025; (1(4)) doi:10.70962/jhi.20250018.

    PMID: 41293556
  3. 3

    OTULIN-related conditions: Report of a new case and review of the literature using GenIA.

    Caballero-Oteyza A, Crisponi L, Peng XP, et al.

    Clinical immunology (Orlando, Fla.) 2024; (265()):110292 doi:10.1016/j.clim.2024.110292.

    PMID: 38914362
  4. 4

    Clinical exome sequencing of 1000 families with complex immune phenotypes: Toward comprehensive genomic evaluations.

    Similuk MN, Yan J, Ghosh R, et al.

    The Journal of allergy and clinical immunology 2022; (150(4)):947-954 doi:10.1016/j.jaci.2022.06.009.

    PMID: 35753512
  5. 5

    Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease.

    Zhou Q, Yu X, Demirkaya E, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2016; (113(36)):10127-32 doi:10.1073/pnas.1612594113.

    PMID: 27559085
  6. 6

    OTULIN-related conditions: Report of a new case and review of the literature using GenIA.

    Caballero-Oteyza A, Crisponi L, Peng XP, et al.

    Research square 2024; doi:10.21203/rs.3.rs-3950863/v2.

    PMID: 38712244

This page is for informational purposes only and does not constitute medical advice. A clinical immunologist or genetics professional should interpret your OTULIN results and guide decisions about family testing.